Literature DB >> 8437963

Measurement of Tc-99m DTPA serum clearance for estimating glomerular filtration rate in children with cancer.

J H Rodman1, D C Maneval, H L Magill, M Sunderland.   

Abstract

Clearance of the radiopharmaceutical Tc-99m DTPA estimated from blood samples with no urine collection can provide a reliable estimate of glomerular filtration rate (GFR) in adults, but has not been well studied in children. The disposition of Tc-99m DTPA was determined in 17 children with cancer, and the influence of binding and study design on the estimates for serum clearance were evaluated. Nine blood samples were obtained over 6 hours in each patient, and serum was assayed for total and free Tc-99m. Free Tc-99m DTPA was determined by ultrafiltration. Estimates of clearance derived from a two-compartment model for ultrafiltrable Tc-99m DTPA were determined from all nine measured concentrations, and these results served as a reference value for GFR in each subject. Total Tc-99m DTPA concentrations also were best described by a two-compartment model, but the median total clearance (35 ml/min) was significantly (p < 0.01) lower than the ultrafiltrate clearance (58 ml/min). The effect of a simplified sampling schedule was assessed from clearance estimates based on a 3-point subset of the ultrafiltrable data. The median clearance of 69 ml/minute was significantly higher (p < 0.01) than the reference GFR. However with a correction factor included to account for the positive bias arising from the limited sampling schedule, the reference estimates for GFR were well predicted (r2 = 0.99) with no significant bias. Ultrafiltrable Tc-99m DTPA serum clearance using a limited sampling schedule can provide a consistent and clinically feasible estimate of glomerular filtration rate in children, but binding in serum and study design are potentially important confounding factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437963

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

1.  Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Authors:  Russell E Ware; Renee C Rees; Sharada A Sarnaik; Rathi V Iyer; Ofelia A Alvarez; James F Casella; Barry L Shulkin; Eglal Shalaby-Rana; C Frederic Strife; John H Miller; Peter A Lane; Winfred C Wang; Scott T Miller
Journal:  J Pediatr       Date:  2010-01       Impact factor: 4.406

2.  Carboplatin-associated ototoxicity in children with retinoblastoma.

Authors:  Ibrahim Qaddoumi; Johnnie K Bass; Jianrong Wu; Catherine A Billups; Amy W Wozniak; Thomas E Merchant; Barrett G Haik; Matthew W Wilson; Carlos Rodriguez-Galindo
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

3.  Comparison of two methods for carboplatin dosing in children with retinoblastoma.

Authors:  Steven Allen; Matthew W Wilson; Amy Watkins; Catherine Billups; Ibrahim Qaddoumi; Barrett H Haik; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

4.  Long-term renal function after treatment for unilateral, nonsyndromic Wilms tumor. A report from the St. Jude Lifetime Cohort Study.

Authors:  Daniel M Green; Mingjuan Wang; Matthew J Krasin; Andrew M Davidoff; DeoKumar Srivastava; Dennis W Jay; Kirsten K Ness; Barry L Shulkin; Sheri L Spunt; Deborah P Jones; Jennifer Q Lanctot; Kyla C Shelton; Rachel C Brennan; Daniel A Mulrooney; Matthew J Ehrhardt; Todd M Gibson; Beth A Kurt; Leslie L Robison; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2020-07-24       Impact factor: 3.167

5.  Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.

Authors:  Najat C Daw; Michael D Neel; Bhaskar N Rao; Catherine A Billups; Jianrong Wu; Jesse J Jenkins; Juan Quintana; Lori Luchtman-Jones; Milena Villarroel; Victor M Santana
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

6.  Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.

Authors:  Ofelia Alvarez; Scott T Miller; Winfred C Wang; Zhaoyu Luo; M Beth McCarville; George J Schwartz; Bruce Thompson; Thomas Howard; Rathi V Iyer; Sohail R Rana; Zora R Rogers; Sharada A Sarnaik; Courtney D Thornburg; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2012-01-31       Impact factor: 3.167

7.  Glomerular hyperfiltration and albuminuria in children with sickle cell anemia.

Authors:  Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Jane S Hankins; Russell E Ware
Journal:  Pediatr Nephrol       Date:  2011-05-11       Impact factor: 3.714

8.  Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.

Authors:  Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Barry L Shulkin; Jane S Hankins; Russell E Ware
Journal:  Am J Hematol       Date:  2012-12-17       Impact factor: 10.047

9.  Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour.

Authors:  Najat C Daw; David Gregornik; John Rodman; Neyssa Marina; Jianrong Wu; Larry E Kun; Jesse J Jenkins; Valerie McPherson; Judith Wilimas; Deborah P Jones
Journal:  Eur J Cancer       Date:  2008-11-06       Impact factor: 9.162

10.  Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients.

Authors:  Vanessa E Millisor; Jessica K Roberts; Yilun Sun; Li Tang; Vinay M Daryani; David Gregornik; Shane J Cross; Deborah Ward; Jennifer L Pauley; Alejandro Molinelli; Rachel C Brennan; Clinton F Stewart
Journal:  Pediatr Nephrol       Date:  2017-06-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.